Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) ((ITP;rhTPO))
Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial
Sponsor: The First Affiliated Hospital of Nanchang University
This PHASE4 trial investigates Primary Immune Thrombocytopenia and is currently ongoing. The First Affiliated Hospital of Nanchang University leads this study, which shows 9 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE4
-
Aug 2025 — Sep 2025 [monthly]
Unknown PHASE4
-
Sep 2024 — Aug 2025 [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2022 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE4
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE4
-
Feb 2019 — Dec 2019 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- The First Affiliated Hospital of Nanchang University
- The First People's Hospital of Yuhang District
- The Third Xiangya Hospital of Central South University
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Xiangyang Central Hospital
For direct contact, visit the study record on ClinicalTrials.gov .